iBio, Inc.
Datakwaliteit: 100%
IBIO
NASDAQ
Manufacturing
Chemicals
€ 2,14
▼
€ 0,06
(-2,51%)
6 months return
—
Momentum
Neutral
5Y revenue growth
-35,91%
Groei
Revenue Growth (5Y)
-35,91%
Onder sectorgemiddelde (1,72%)
Revenue (1Y)77,78%
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-43,94%
Boven sectorgemiddelde (-54,47%)
ROIC-34,52%
Net Margin-8245,67%
Op. Margin-8491,00%
Veiligheid
Debt / Equity
N/A
Current Ratio9,04
Interest Coverage-145,56
Waardering
PE (TTM|NTM)
-3,09 | -7,45
Onder sectorgemiddelde (-1,50)
P/B Ratio1,35
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Revenue declined -35,91% annually over 5 years
Negative free cash flow of -19,19 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 113,69%
Capital intensive — 187,67% of revenue goes to capex
Price History
Financiële Trends
Koersdoel Analisten
6 analisten
Buy
+151.4%
upside to target
Huidig
€ 2,14
Consensus Target
€ 5,37
€ 4,20
Laag
€ 7,00
Hoog
Vooruitzicht
Forward K/W
-7,45
Forward WPA
-€ 0,29
Omzet Sch.
120.000,0
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,06
·
Rev Est: 20.000,0
| Q12025 | 2026-Q1 | 2026-Q2 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|---|---|
| Reported | -€ 0,49 | -€ 0,11 | -€ 0,08 | -€ 0,32 | -€ 0,11 | -€ 0,09 | — | — |
| Estimate | -€ 0,32 | -€ 0,06 | -€ 0,06 | -€ 0,37 | -€ 0,07 | -€ 0,07 | -€ 0,06 | -€ 0,06 |
| Verrassing | -53,12% | -73,78% | -29,66% | +12,33% | -50,01% | -38,46% | — | — |
Growth
Rev 5Y: -35,91% · Earnings 1Y: N/A
Growth
Rev 5Y: -35,91% · Earnings 1Y: N/A| Revenue Growth (1Y) | 77,78% | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | -35,91% | Earnings Growth (5Y) | N/A |
Profitability
ROE: -43,94% · Net Margin: -8245,67%
Profitability
ROE: -43,94% · Net Margin: -8245,67%| Revenue (TTM) | 300.000,0 | Net Income (TTM) | -24,74 M |
| ROE | -43,94% | ROA | -38,49% |
| Gross Margin | N/A | Operating Margin | -8491,00% |
| Net Margin | -8245,67% | Free Cash Flow (TTM) | -19,19 M |
| ROIC | -34,52% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 9,04
Safety
D/E: N/A · Current: 9,04| Debt / Equity | N/A | Current Ratio | 9,04 |
| Interest Coverage | -145,56 | Asset Turnover | 0,00 |
| Working Capital | 47,47 M | Tangible Book Value | 52,22 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -3,09 · EV/EBITDA: N/A
Valuation
P/E: -3,09 · EV/EBITDA: N/A| P/E Ratio | -3,09 | Forward P/E | -7,45 |
| P/B Ratio | 1,35 | P/S Ratio | 255,05 |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 637,62 | Fwd Earnings Yield | N/A |
| FCF Yield | -25,08% | ||
| Market Cap | 76,51 M | Enterprise Value | 47,84 M |
Per Share
EPS: -1,00 · FCF/Share: -0,56
Per Share
EPS: -1,00 · FCF/Share: -0,56| EPS (Diluted TTM) | -1,00 | Revenue / Share | 0,01 |
| FCF / Share | -0,56 | OCF / Share | -0,54 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 77,57% · CapEx/Rev: 187,67%
Efficiency
FCF Conv: 77,57% · CapEx/Rev: 187,67%| CapEx / Revenue | 187,67% | FCF Conversion | 77,57% |
| SBC-Adj. FCF | -20,55 M | Growth Momentum | 113,69 |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 400.000,0 | 225.000,0 | 0,0 | 2,38 M | 2,37 M |
| Net Income | -18,38 M | -24,91 M | -65,01 M | -50,30 M | -23,21 M |
| EPS (Diluted) | -1,75 | -6,50 | -5,31 | -5,78 | — |
| Gross Profit | — | — | — | 2,17 M | 909.000,0 |
| Operating Income | -18,60 M | -16,63 M | -29,34 M | -49,69 M | -31,11 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 8,31 M | 5,19 M | 10,33 M | 17,73 M | 9,99 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 212.000,0 | 172.000,0 | 83.000,0 | 1,41 M | 2,45 M |
| Income Tax | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 23,19 M | 28,73 M | 41,21 M | 99,41 M | 146,97 M |
| Total Liabilities | 8,31 M | 7,41 M | 25,83 M | 35,92 M | 38,40 M |
| Shareholders' Equity | 14,88 M | 21,32 M | 15,38 M | 63,49 M | 108,59 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 8,58 M | 14,21 M | 4,30 M | 22,68 M | 77,40 M |
| Current Assets | 9,72 M | 15,67 M | 26,26 M | 45,07 M | 104,60 M |
| Current Liabilities | 6,11 M | 3,84 M | 21,58 M | 30,44 M | 6,65 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -3,1 | -1,5 |
| P/B | 1,4 | 1,6 |
| ROE % | -43,9 | -54,5 |
| Net Margin % | -8245,7 | -41,5 |
| Rev Growth 5Y % | -35,9 | 1,7 |
| D/E | — | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"IBIO","listing_kind":"stock","pathname":"/stocks/ibio","exchange":"NASDAQ","country":"US"}}